Calidi Biotherapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Calidi Biotherapeutics, Inc. (CLDI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $303.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-05-14
- Calidi Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $303.00K, a 11.40% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $295.00K, a 11.32% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $288.00K, a 11.63% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $278.00K, a 10.76% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.13M, a 31.13% increase from fiscal 2023.
- Calidi Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $864.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-03-31 | $303.00K 10-Q · filed 2025-05-14 | $598.00K derived: sum of 2 quarters · filed 2025-05-14 | $886.00K derived: sum of 3 quarters · filed 2025-05-14 | $1.16M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $583.00K derived: sum of 2 quarters · filed 2025-03-31 | $861.00K derived: sum of 3 quarters · filed 2025-03-31 | $1.13M 10-K · filed 2025-03-31 |
| 2024-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $566.00K derived: sum of 2 quarters · filed 2024-11-12 | $838.00K 10-Q · filed 2024-11-12 | $1.10M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | $278.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $550.00K 10-Q · filed 2024-08-13 | $815.00K derived: sum of 3 quarters · filed 2025-05-14 | $1.07M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | $272.00K 10-Q · filed 2025-05-14 | $537.00K derived: sum of 2 quarters · filed 2025-05-14 | $795.00K derived: sum of 3 quarters · filed 2025-05-14 | $1.05M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $523.00K derived: sum of 2 quarters · filed 2025-03-31 | $774.00K derived: sum of 3 quarters · filed 2025-03-31 | $864.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $509.00K derived: sum of 2 quarters · filed 2024-11-12 | $599.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $341.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $90.00K 10-Q · filed 2024-05-14 | |||
| 2022-09-30 | $9.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |